Novavax (NVAX) Accumulated Expenses (2010 - 2026)

Novavax's Accumulated Expenses history runs 17 years deep, the most recent figure standing at $103.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 22.05% year-over-year to $103.0 million; the TTM figure through Mar 2026 stood at $103.0 million (down 22.05% YoY), while the FY2025 annual figure was $107.2 million, down 49.25% from the prior year.
• Accumulated Expenses was $103.0 million for Q1 2026 at Novavax, down from $107.2 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $591.2 million in Q4 2022 to a low of $86.7 million in Q2 2025.
• Historically, Accumulated Expenses has averaged $315.4 million across 5 years, with a median of $257.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses surged 276.74% in 2022, then plunged 65.27% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $591.2 million in 2022, then sank by 33.24% to $394.7 million in 2023, then tumbled by 46.5% to $211.2 million in 2024, then tumbled by 49.25% to $107.2 million in 2025, then decreased by 3.86% to $103.0 million in 2026.
• The last three Accumulated Expenses figures came in at $103.0 million (Q1 2026), $107.2 million (Q4 2025), and $115.6 million (Q3 2025), per Business Quant data.